Organization
Hoag Family Cancer Institute and University of Southern California
18 abstracts
Abstract
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, Hunstman Cancer Hospital, University of Utah Health, University of Kentucky, Markey Cancer Center, Department of Medical Oncology, Mercy Medical Center,
Abstract
Quality metrics analysis in patients who received Lutetium-177 PSMA-617 (177Lu–PSMA) therapy in a real-world practice setting.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Hoag Family Cancer Institute and University of Southern California, Department of Radiological Sciences,
Abstract
In-hospital outcomes of acute pulmonary embolism admissions in individuals with genitourinary cancers: Insights from a national population study in the United States.Org: Hoag Family Cancer Institute and University of Southern California, University of California Irvine, Wayne State University School of Medicine,
Abstract
Evaluation of concordance between blood-based and matched tissue molecular testing in a regional cancer center.Org: Hoag Family Cancer Institute and University of Southern California, Newport Beach, CA,
Abstract
Real-world treatment patterns with lutetium-177-PSMA-617 (177-Lu-PSMA) in patients with metastatic castrate-resistant prostate cancer (mCRPC).Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, University of California, Irvine, Irvine, CA, Department of Hematology/Oncology, University of California Irvine Medical Center, Hoag Family Cancer Institute and University of Southern California,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Utility of artificial intelligence-based genomic classification of occult malignancies in clinical practice.Org: Hoag Family Cancer Institute and University of Southern California, Newport Beach, CA,
Abstract
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.Org: University of California Irvine School of Medicine, Barbara Ann Karmanos Cancer Institute, Lombardi Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care,
Abstract
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.Org: University of Cincinnati Medical Center, SWOG Statistical Center, University of Cincinnati College of Medicine, Fred Hutchinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.Org: Mayo Clinic Florida, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), Karmanos Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Abstract
Somatic profiling guides germline genetic testing in patients with mutations in cancer predisposition genes.Org: Hoag Family Cancer Institute and University of Southern California, Hoag Memor Hosp,
Abstract
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, MD Anderson Cancer Center, Moffitt Cancer Center and Research Institute, Nebraska Cancer Specialists,
Abstract
A phase I study of isunakinra, an IL-1 alfa/beta inhibitor, in combination with nivolumab for patients with solid tumors refractory to standard therapies.Org: Hoag Family Cancer Institute and University of Southern California, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, Buzzard Pharmaceuticals AB, Buzzard Pharmaceuticals,
Abstract
Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck.Org: UC San Diego Moores Cancer Center, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Hoag Memor Hosp, Hoag Family Cancer Institute and University of Southern California,
Abstract
Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma.Org: UCI Medical Center, Hoag Family Cancer Institute and University of Southern California, University of California Irvine, Pfizer, Pfizer Inc., London, United Kingdom,
Abstract
Association between time to treatment initiation and survival in metastatic renal cell cancer: A population-based study of 5,193 cases from the California Cancer Registry (2010-2019).Org: Hoag Family Cancer Institute and University of Southern California, Cancer Registry of Greater California (CRGC), Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, University of California Irvine,
Abstract
The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,